CDKN2A and neoplasm: This study aimed to evaluate PD-L1 expression in vSCC tumors and to look for the correlation of this biomarker with clinical and pathological features of vSCC patients including TILs, TAMs as well as p16INK4a and high risk (hr) DNA-HPV status in the primary tumor.